Fig. 1From: Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trialPatient disposition. aPatients were considered to have completed the study if they received study treatment at Week 24 and completed the follow-up contact at Week 25 (±3 days). ITT, intent-to-treat; UMEC, umeclidinium; VI, vilanterolBack to article page